IL-17A and IL-17F antagonists

Details IL-17A and IL-17F antagonists IL-17A and IL-17F antagonists

2009-02-12

2010-11-30

Jiang, Dong (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S351000, C435S069700

Reexamination Certificate

active

07842665

ABSTRACT:
The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same.

REFERENCES:
patent: 6569645 (2003-05-01), Chen et al.
patent: 6579520 (2003-06-01), Chen et al.
patent: 2002/0119130 (2002-08-01), Eaton et al.
patent: 2002/0182673 (2002-12-01), Chen et al.
patent: 2003/0008815 (2003-01-01), Chen et al.
patent: 2003/0040471 (2003-02-01), Watson et al.
patent: 2003/0073623 (2003-04-01), Drmanac et al.
patent: 2003/0092881 (2003-05-01), Gorman
patent: 2003/0100051 (2003-05-01), Ruben et al.
patent: 2003/0046196 (2003-06-01), Baughn et al.
patent: 2003/0180857 (2003-09-01), Eaton et al.
patent: 2003/0181669 (2003-09-01), Eaton et al.
patent: 2003/0199041 (2003-10-01), Presnell et al.
patent: 2004/0009479 (2004-01-01), Wohlgemuth et al.
patent: 2004/0048249 (2004-03-01), Tang et al.
patent: 2004/0091959 (2004-05-01), Baker et al.
patent: 2004/0097447 (2004-05-01), Dobie
patent: WO 96/29408 (1996-09-01), None
patent: WO 98/37193 (1998-08-01), None
patent: WO 98/49307 (1998-11-01), None
patent: WO 99/07848 (1999-02-01), None
patent: WO 99/14240 (1999-03-01), None
patent: WO 01/04304 (2001-01-01), None
patent: WO 01/46420 (2001-06-01), None
patent: WO 01/66722 (2001-09-01), None
patent: WO 01/90358 (2001-11-01), None
patent: WO 02/04519 (2002-01-01), None
patent: WO 02/38764 (2002-05-01), None
patent: WO 2005/010044 (2005-02-01), None
Aggarwal et al.,J. Biol. Chem., 278: 1910-1914, 2003.
Barczyk et al.,Respir. Med., 97: 726, 2003.
Cai et al.,Cytokine, 16: 10-21, 2001.
Chaband et al.,Arthritis Rheum., 42: 963-970, 1999.
Database EMBL Online! EBI Feb. 18, 2002, Acc. No. AL133097.
Database EMBL Online! EBI Nov. 16, 1998, Acc. No. A1261248.
Dumont, F.J.,Expert Opinion Therapeutic Patents(2003) 13 (3) 287-303.
Fossiez et al.,Int. Rev. Immunol.16: 541-551, 1998.
Fossiez et al.,J. Exp. Med., 183: 2593, 1996.
GenBank Acc. No. AV010326 (May 10, 1999).
Gerritsen et al.,Br. J. Pharmacol., 140 (4): 595-610, 2003.
Haudenschild et al.,J. Biol. Chem.277 (6): 4309-4316, 2002.
Hellings et al.,Am. J. Respir. Cell Mol. Biol., 28:42, 2003.
Hurst et al.,J. Immunol.169: 443, 2002.
Hymowitz et al.,EMBO J.20: 5332-5342, 2001.
Ivanov et al.,European Respiratory Journal22, 44 Supple: 42s, 2003.
Jovanovic et al.,J. Immunol.160: 3513, 1998.
Kawaguchi et al.,J. Immunol.167, 4430-4435, 2001.
Kotake et al.,J. Clin. Invest.103: 1345-1352, 1999.
Laan et al.,Eur. Respir. J., 21: 387, 2003.
Le Grand et al.,Arthritis Rheum.44: 2078-2083, 2001.
Linden et al.,Eur. Respir. J.15: 973, 2000.
Linden et al.,Int. Arch. Allergy Immunol.126: 179, 2001.
Lubberts,Current Opinion in Investigational Drugs4(5): 572-577, May 2003.
Matusevicius et al.,Mult. Scler., 5: 101-104, 1999.
Molet et al.,J. Allergy Clin. Immunol., 108: 430, 2001.
Moseley et al.,Cytokine Growth Factor Rev., 14(2): 155-174, Apr. 2003.
Nakae et al.,J. Immunol., 171(11): 6173-6177, 2003.
Novatchkova et al.,Trends Biochem. Sci.28(5): 226-229, May 2003.
Oda et al.,Am. J. Respir. Crit. Care Med.171: 12, 2005.
Parnet et al.,J. Biol. Chem.271(8): 3967-3970, 1996.
Pellagatti et al.,Br. J. Haematol., 125(5): 576-583, 2004.
Rahman et al.,Clin. Immunol.115: 268, 2005.
Rouvier et al.,J. Immunol., 150(12): 5445-5456, 1993.
Shalom-Barek et al.,J. Biol. Chem.273: 27467, 1998.
Starnes et al.,J. Immunol.167: 4137-4140, 2001.
Tsibris et al.,Biochem. Biophys. Res. Commun.312(1): 249-254, 2003.
UniProt Database Accession No. Q8BP15, Mar. 2003.
UniProt Database Accession No. Q8K4X1, Oct. 2002.
UniProt Database Accession No. Q8N2D7, Oct. 2002.
Van Bezooijen et al., J. Bone Miner Res., 14: 1513-1521, 1999.
Yan et al.,Science, 290(20: 523-527, 2000.
Yao et al.,Cytokine, 794, 1997.
Yao et al.,Immunity, 3(6): 811-821, 1995.
Yao et al.,J. Immunol., 155: 5483-5486, 1995.
Ye et al.,Am. J. Respir, Cell Mol. Biol., 25: 335, 2001.
Incyte Corporation Accession No. LIN1878466F6, 1997.
TIGR Tentative Human Consensus Accession No. THC—THC160674, 1997.

Affiliated with

Also associated with

Rating

IL-17A and IL-17F antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IL-17A and IL-17F antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-17A and IL-17F antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4213306